Myobloc Approved for the Treatment of Chronic Sialorrhea
The Food and Drug Administration (FDA) has approved Myobloc (rimabotulinumtoxinB injection; US WorldMeds) for the treatment of chronic sialorrhea in adults.
Neurodegenerative Diseases
Amyotrophic Lateral Sclerosis Risk and the Role of Genetics
Inherited and noninherited genetic factors contribute equally to the risk for developing amyotrophic lateral sclerosis (ALS), and first-degree relatives of people with ALS tend to have a higher risk for the disease compared with the general population, even in the absence of known ALS-associated genetic mutations.
Trial Investigating Fosmetpantotenate for Rare Neurologic Disorder Misses Primary End Point
A phase 3 trial evaluating an investigational therapy for the treatment of pantothenate kinase-associated neurodegeneration did not meet its primary or secondary end points.
Respiratory Function May Herald Progression of Amyotrophic Lateral Sclerosis
Three trajectories of respiratory function have been identified in patients with amyotrophic lateral sclerosis.
Focal Epilepsy Associated With Acceleration in Progressive Cortical Thinning
Focal epilepsy may accelerate widespread progressive cortical thinning to a greater degree than that observed in normal aging.
Green Tea Extract Shows No Significant Benefit for Multiple System Atrophy
Findings from PROMESA tiral show orally administered epigallocatechin gallate, a component extracted from green tea, treatment produced no significant benefits in modifying disease progression for people with multiple system atrophy.
High BMI, Weight Gain Associated With Low ALS Risk Decades Later
High pre-diagnostic body mass index and weight gain are associated with a lower risk for ALS several decades later. The strength of the association between BMI and ALS risk increases up to 50 years after BMI measurement.
Automated Assays Detecting Plasma Aβ42 and Aβ40 Are Predictive of Aβ Status in AD
Using fully automated Elecsys immunoassays, investigators found that plasma levels of the peptides Aβ1-42 (Aβ42) and Aβ1-40 (Aβ40) can predict levels of β-amyloid status in all stages of Alzheimer disease.
Deferiprone May Slow Disease Progression in Pantothenate Kinase-Associated Neurodegeneration
Deferiprone was well-tolerated, safe, and appears to slow disease progression in pantothenate kinase-associated neurodegeneration.
Alzheimer Disease, Dementia Linked to Increased Seizure Risk
Patients with dementia or Alzheimer disease (AD) have a significantly increased risk for seizures compared with patients without AD or dementia.
Next post in Neurodegenerative Diseases
